Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time

 Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time

Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time

Shots:

  • The companies shared the additional efficacy and safety data of the ACTT-2 study demonstrating baricitinib + remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir as monothx
  • The biggest benefits were observed in patients requiring supplemental oxygen (grade 5 on the eight-point ordinal scale) and those who required high-flow oxygen/non-invasive ventilation (grade 6) at baseline
  • Additionally, Eli Lilly is in talks with the US FDA for EUA of baricitinib (JAK1/JAK2 inhibitor licensed to Lilly from Incyte) to treat hospitalized patients with COVID-19

    Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Strateos Blog

    Related News: Eli Lilly and Incyte’s Olumiant + Gilead’s Veklury Reduce Time to Recovery in Hospitalized Patients with COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post